• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-K filed by Alaunos Therapeutics Inc.

    3/31/25 4:18:18 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCRT alert in real time by email

    Unavailable

    Get the next $TCRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRT

    DatePrice TargetRatingAnalyst
    10/4/2022$3.00Overweight
    Wells Fargo
    More analyst ratings

    $TCRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Postma Robert W was granted 20,804 shares, increasing direct ownership by 251% to 29,083 units (SEC Form 4)

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:42:09 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Weis Holger

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:33:33 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vieser Jaime was granted 17,465 shares, increasing direct ownership by 67% to 43,359 units (SEC Form 4)

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:26:04 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo resumed coverage on Alaunos Therapeutics with a new price target

      Wells Fargo resumed coverage of Alaunos Therapeutics with a rating of Overweight and set a new price target of $3.00

      10/4/22 7:18:05 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

      HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) (the "Company") today announced that it has entered into a definitive agreement with certain investors (the "SPA") for the purchase and sale of an aggregate of 610,399 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.36 per share (or pre-funded warrant in lieu thereof) in a registered direct offering (the "Offering") on June 20, 2025 based on the 5-day average Nasdaq official closing price. The aggregate gross proceeds to the Company of this offering are expected to be approximately $2.0 million, before deducting the offering expenses payable by the Company. The Com

      6/23/25 8:00:00 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

      NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today issued a public statement urging Alaunos Therapeutics, Inc. (NASDAQ:TCRT) to accept and act upon the term sheet previously facilitated through a leading Wall Street Bank. As disclosed in PMGC Capital's May 14, 2025 press release, available on the PMGC Holdings website, PMGC Capital holds a significant ownership position in Alaunos and continues to act in the best interest of all shareholders. The proposed financing sent to the board on 5/25/2025, introduced by PMGC Capital and led by a leading wall street bank, represents a compe

      6/18/25 9:52:27 AM ET
      $ELAB
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

      NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital," "we," "our," or "us"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (NASDAQ:TCRT). PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company's outstanding shares of common stock, based on Alaunos' Preliminary Schedule 14A filed with the U.S. Securities and Exchange Commission, indicating 1,639,521 shares of common stock outstanding as of May 5, 2025.

      5/14/25 8:00:00 AM ET
      $ELAB
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care